Drug notes:
Also Clin1 neuropathic pain, Clin1 bipolar disorder; RAP-199 Clin0 undisclosed; 2 undisclosed programs RD pain, hearing disorders
About:
Rapport Therapeutics is identifying precision therapeutics to treat several central nervous system disorders. Central nervous systems disorders (CNS) are often treated with therapies that target the whole nervous system, while typically CNS diseases arise in specific cell types or restricted brain regions. Using their RAP technology platform, Rapport is creating small molecule therapies to deliver more effective and safer treatments. RAPs are receptor-associated proteins that enable Rapport to develop CNS drugs that are specific for receptor variants and neuroanatomical regions associated with certain diseases. Rapport’s lead program, RAP-219, is in clinical trials for patients with focal epilepsy.
Jobs:
VP/SVP, Clinical Development, CNS 1325 Boylston St., Suite 401, Boston, MA 02215|100+ days ago